Association of dose escalation of octreotide long‐acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors-Reference-Cited by-同舟云学术

Association of dose escalation of octreotide long‐acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors

Published:2015-02-26 Issue:6 Volume:4 Page:864-870
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Al‐Efraij Khalid¹,Aljama Mohammed A.²,Kennecke Hagen Fritz³

Affiliation:

1. Division of Respirology University of British Columbia Vancouver British Columbia Canada

2. Division of Hematology University of British Columbia Vancouver British Columbia Canada

3. Division of Medical Oncology British Columbia Cancer Agency University of British Columbia Vancouver British Columbia Canada

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.435

Reference31 articles.

1. A 5-decade analysis of 13,715 carcinoid tumors

2. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

3. A Three-Decade Analysis of 3,911 Small Intestinal Neuroendocrine Tumors: The Rapid Pace of No Progress

4. Evaluating the Characteristics and the Management of Patients With Neuroendocrine Tumors Receiving Octreotide LAR During a 6-Year Period

5. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization;Reubi J. C.;Cancer Res.,1994

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well‐differentiated small intestine neuroendocrine tumours;Journal of Neuroendocrinology;2024-07-08

2. Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database;Clinics and Research in Hepatology and Gastroenterology;2023-08

3. Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists;Cancer Treatment Reviews;2023-06

4. Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care;Endocrine-Related Cancer;2023-04-05

5. Bouveret Syndrome simultaneous with an incidental solitary Gastric Neuroendocrine Tumor in a 44-year-old female - A Case Report;Annals of Medicine & Surgery;2023-04